MetaVia Inc. 8-K

What Happened
MetaVia Inc. (MTVA) filed an 8-K on March 18, 2026, announcing that the Institutional Review Board at Clinical Pharmacology of Miami approved the Company’s Phase 1 Part 3 clinical trial of DA-1726, a dual oxyntomodulin analog agonist that targets GLP-1 and glucagon receptors. The Company issued a press release attached as Exhibit 99.1 and said initial dosing is planned for April 2026 with data expected in the fourth quarter of 2026.

Key Details

• Trial enrollment: 40 obese, otherwise healthy adults total, split across two parts (20 subjects per part).
• Randomization: 4:1 active to placebo in each part (16 active; 4 placebo per part).
• Dosing regimens: Part 3A — one-step titration: 16 mg for 4 weeks, then 48 mg for 12 weeks; Part 3B — two-step titration: 16 mg for 4 weeks, 32 mg for 4 weeks, then 64 mg for 8 weeks.
• Endpoints: Primary — safety and tolerability (AEs, serious AEs, treatment-emergent AEs, AEs leading to discontinuation); Secondary/exploratory — PK profiling and metabolic, glycemic, lipid, body composition (weight, waist, BMI) and other cardiometabolic measures.
• Timeline: dosing to start in April 2026; top-line or initial data expected Q4 2026.

Why It Matters
This filing confirms regulatory/IRB clearance to advance DA-1726 into the next part of human testing, a material operational milestone for MetaVia’s lead program. The trial focuses on safety, tolerability and PK while collecting metabolic and weight-related signals that investors often watch for in obesity/GLP-1–related programs. Key near-term catalysts for shareholders are the start of dosing (expected April 2026) and the data readout targeted for Q4 2026. The company’s disclosure also includes standard forward-looking statement cautions that timelines and results may change.